Bellevue Life Sciences Acquisition CorpNASDAQ:BLACNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE10.8300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots10.6900/ 9
- Ask / Lots17.3200/ 2
- Open / Previous Close0.0000 / 10.8300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | BLAC |
|---|
Jul 18, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FRLA, BLAC, SLAM on Behalf of Shareholders, from 11:50PM ET on Thursday Jul 18, 2024 by Dow Jones
11:50PM ET on Thursday Jul 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bellevue Life Sciences Acquisition Corp | 43.8M | 554.2x | --- |
DUET Acquisition Corp | 43.8M | 267.1x | --- |
PMV Consumer Acquisition Corp | 43.9M | -504.9x | --- |
Daxor Corp | 43.8M | -248.8x | --- |
Yotta Acquisition Corp | 44.0M | 54.6x | --- |
Mountain Crest Acquisition Corp V | 43.5M | -13.8x | --- |
Company Information
Bellevue Life Sciences Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company has not selected any business combination target, and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company may pursue an acquisition opportunity in any business industry or sector. The Company intends to acquire and manage a business in the healthcare industry, more specifically in the biotechnology sector. The Company neither engaged in any operations nor generated any revenues.
Contact Information
- Headquarters
- 10900 Ne 4Th Street, Suite 2300BELLEVUE, WA, United States 98004
- Phone
- 425-635-7700
- Fax
- ---
Executives
- Chief Executive Officer, Director
- Kuk Hyoun Hwang
- Chief Financial Officer
- David Yoo
- Director
- Jun Chul Whang
- Independent Director
- Sang Hyun Kim
- Independent Director
- Phil Geon Lee
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $43.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 4.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.02 |
Book Value | $5.78 |
P/E Ratio | 554.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
